Remdesivir and Dexamethasone: The Two Eligible Candidate Drugs Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) Infection

Y. Sikandar, Ilora Kheya, R. Noor
{"title":"Remdesivir and Dexamethasone: The Two Eligible Candidate Drugs Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) Infection","authors":"Y. Sikandar, Ilora Kheya, R. Noor","doi":"10.4103/BMRJ.BMRJ_10_20","DOIUrl":null,"url":null,"abstract":"Lots of research based on drug designing as well as in silico study, cell culture/animal model study, and the clinical trials are being conducted perceive the suitable therapeutic drugs and to develop vaccines in order to alleviate the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although there are still no vaccines, some potential antiviral drugs have been repurposed including remdesivir, chloroquine/hydroxychloroquine, ribavirin, favipiravir, cepharanthine, and lopinavir/ritonavir, of which remdesivir has been mostly accepted for the treatment purpose because of its multitarget actions. Besides, the immunosuppressive agent, dexamethasone, evolved with the capacity to protect the severely affected COVID-19 patients from death to some extent. The current review, thus, emphasized on both remdesivir and dexamethasone as the successful remedies for the ongoing pandemic and detected the possible mode of action of dexamethasone.","PeriodicalId":34293,"journal":{"name":"Biomedical Research Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Research Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/BMRJ.BMRJ_10_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Lots of research based on drug designing as well as in silico study, cell culture/animal model study, and the clinical trials are being conducted perceive the suitable therapeutic drugs and to develop vaccines in order to alleviate the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2. Although there are still no vaccines, some potential antiviral drugs have been repurposed including remdesivir, chloroquine/hydroxychloroquine, ribavirin, favipiravir, cepharanthine, and lopinavir/ritonavir, of which remdesivir has been mostly accepted for the treatment purpose because of its multitarget actions. Besides, the immunosuppressive agent, dexamethasone, evolved with the capacity to protect the severely affected COVID-19 patients from death to some extent. The current review, thus, emphasized on both remdesivir and dexamethasone as the successful remedies for the ongoing pandemic and detected the possible mode of action of dexamethasone.
瑞德西韦和地塞米松:两种抗严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)感染的候选药物
为了缓解由严重急性呼吸系统综合征冠状病毒引起的COVID-19大流行,正在进行大量基于药物设计、计算机研究、细胞培养/动物模型研究和临床试验的研究,以寻找合适的治疗药物和开发疫苗2。虽然目前还没有疫苗,但一些潜在的抗病毒药物已被重新利用,包括瑞德西韦、氯喹/羟氯喹、利巴韦林、法匹拉韦、头孢anthine和洛匹那韦/利托那韦,其中瑞德西韦因其多靶点作用而被广泛接受用于治疗目的。此外,免疫抑制剂地塞米松也在进化,在一定程度上保护了COVID-19重症患者的死亡。因此,目前的审查强调瑞德西韦和地塞米松是目前大流行的成功补救措施,并发现了地塞米松可能的作用方式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信